J.F. Baurain

621 total citations
26 papers, 327 citations indexed

About

J.F. Baurain is a scholar working on Oncology, Immunology and Reproductive Medicine. According to data from OpenAlex, J.F. Baurain has authored 26 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 6 papers in Immunology and 6 papers in Reproductive Medicine. Recurrent topics in J.F. Baurain's work include Cancer Immunotherapy and Biomarkers (7 papers), Ovarian cancer diagnosis and treatment (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). J.F. Baurain is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Ovarian cancer diagnosis and treatment (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). J.F. Baurain collaborates with scholars based in Belgium, France and United States. J.F. Baurain's co-authors include J-P. Machiels, Marc Van den Eynde, Filomena Mazzeo, L. Thomas, Pauline Richez, Isabelle Tromme, Catherine Legrand, Niko Speybroeck, Serge Leyvraz and Thomas Jouary and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

J.F. Baurain

23 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.F. Baurain Belgium	9	191	102	87	52	50	26	327
Julie Y. Tse United States	14	173 0.9×	129 1.3×	17 0.2×	27 0.5×	64 1.3×	40	446
S Seeber Germany	7	139 0.7×	211 2.1×	191 2.2×	121 2.3×	26 0.5×	10	519
Mariana Petaccia de Macêdo Brazil	15	395 2.1×	135 1.3×	35 0.4×	105 2.0×	90 1.8×	69	636
T. Rinda Soong United States	12	124 0.6×	106 1.0×	24 0.3×	49 0.9×	39 0.8×	35	475
George Blumenschein United States	10	215 1.1×	87 0.9×	31 0.4×	37 0.7×	79 1.6×	20	336
D. Hungermann Germany	11	265 1.4×	173 1.7×	27 0.3×	18 0.3×	14 0.3×	23	555
Ashleigh C. McEvoy Australia	13	265 1.4×	195 1.9×	37 0.4×	64 1.2×	10 0.2×	17	481
Anuradha Bulusu United States	12	188 1.0×	129 1.3×	54 0.6×	133 2.6×	155 3.1×	19	576
Brigida Anna Maiorano Italy	15	343 1.8×	125 1.2×	92 1.1×	145 2.8×	49 1.0×	58	531
Birgitte Ravn Juhl Denmark	12	111 0.6×	176 1.7×	10 0.1×	105 2.0×	42 0.8×	25	439

Countries citing papers authored by J.F. Baurain

Since Specialization

Citations

This map shows the geographic impact of J.F. Baurain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.F. Baurain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.F. Baurain more than expected).

Fields of papers citing papers by J.F. Baurain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.F. Baurain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.F. Baurain. The network helps show where J.F. Baurain may publish in the future.

Co-authorship network of co-authors of J.F. Baurain

This figure shows the co-authorship network connecting the top 25 collaborators of J.F. Baurain. A scholar is included among the top collaborators of J.F. Baurain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.F. Baurain. J.F. Baurain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baurain, J.F., Antoîne Italiano, Madona Sakkal, et al.. (2024). 1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors. Annals of Oncology. 35. S692–S692. 2 indexed citations

Dańska-Bidzińska, Anna, Vanda Salutari, Ali̇ Ayhan, et al.. (2024). 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study. Annals of Oncology. 35. S561–S561. 1 indexed citations

Piperno‐Neumann, Sophie, Piotr Rutkowski, J.F. Baurain, et al.. (2023). LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial. Annals of Oncology. 34. S1289–S1290.

Baurain, J.F., et al.. (2023). Immune checkpoint inhibitor refractory colitis leading to total colectomy in a melanoma patient. Acta Gastro Enterologica Belgica. 86(2). 371–373.

Vergote, Ignace, Hannelore Denys, Sevilay Altıntaş, et al.. (2022). Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. Facts Views and Vision in ObGyn. 14(2). 111–120. 2 indexed citations

Rodriguez, J.M. Piulats, et al.. (2022). 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma. Annals of Oncology. 33. S924–S924. 2 indexed citations

Monk, Bradley J., Toon Van Gorp, Domenica Lorusso, et al.. (2021). O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results. A7.2–A8. 1 indexed citations

Valabrega, Giorgio, Bhavana Pothuri, Ana Oaknin, et al.. (2020). 819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology. 31. S619–S619. 8 indexed citations

Hillemanns, Peter, et al.. (2020). 881TiP A multi-centre, open-label phase II trial of the combination of VB10.16 and atezolizumab in patients with advanced or recurrent, non-resectable HPV16 positive cervical cancer. Annals of Oncology. 31. S645–S646. 4 indexed citations

10.

Pothuri, Bhavana, Sileny Han, Florian Heitz, et al.. (2020). 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology. 31. S612–S613. 5 indexed citations

11.

Ascierto, Paolo A., Lars Bastholt, Peter Möhr, et al.. (2017). EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL). European Journal of Cancer. 72. S128–S128. 1 indexed citations

12.

Awada, Ahmad, Paal Brunsvig, Øystein Rekdal, et al.. (2015). 528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours. European Journal of Cancer. 51. S113–S113. 5 indexed citations

13.

Vergote, I., Ana Oaknin, J.F. Baurain, et al.. (2014). A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. European Journal of Cancer. 50(14). 2408–2416. 16 indexed citations

14.

Leyvraz, Serge, Sophie Piperno‐Neumann, Stefan Suciu, et al.. (2014). Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Annals of Oncology. 25(3). 742–746. 92 indexed citations

15.

Tromme, Isabelle, Brecht Devleesschauwer, Philippe Beutels, et al.. (2014). Health-related quality of life in patients with melanoma expressed as utilities and disability weights. British Journal of Dermatology. 171(6). 1443–1450. 23 indexed citations

16.

Tromme, Isabelle, Catherine Legrand, Liliane Marot, et al.. (2012). Availability of digital dermoscopy in daily practice dramatically reduces the number of excised melanocytic lesions: results from an observational study. British Journal of Dermatology. 167(4). 778–786. 66 indexed citations

17.

Eynde, Marc Van den, J.F. Baurain, Filomena Mazzeo, & J-P. Machiels. (2011). Epidermal growth factor receptor targeted therapies for solid tumours.. DIAL (Catholic University of Leuven). 66(1). 10–7. 30 indexed citations

18.

Eynde, Marc Van den, et al.. (2011). EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED THERAPIES FOR SOLID TUMOURS. Acta Clinica Belgica. 66(1). 10–17. 27 indexed citations

19.

Boterberg, Tom, Paul M. Clément, E. Joosens, et al.. (2011). 8744 POSTER Extended Use of Adjuvant TMZ in Newly Diagnosed GBM Patients is Safe – Results From the Safety Analysis of the PATSGO Trial. European Journal of Cancer. 47. S587–S587. 1 indexed citations

20.

Sadones, Jan, C. Chaskis, E. Joosens, et al.. (2006). A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results. Journal of Clinical Oncology. 24(18_suppl). 1558–1558. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact